NCT07397273

Brief Summary

The purpose of the present study was to examine the effectiveness of acute A-GPC supplementation on upper and lower body muscular strength, endurance, power, and global levels of activation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 2, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 9, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

March 16, 2026

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 16, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 16, 2026

Completed
Last Updated

February 9, 2026

Status Verified

February 1, 2026

Enrollment Period

2 months

First QC Date

February 2, 2026

Last Update Submit

February 2, 2026

Conditions

Healthy Adult Participants

Keywords

supplementationisometricelectromyographyWingate Anaerobic Testmuscular powerergogenic aid

Outcome Measures

Primary Outcomes (2)

  • Maximal Voluntary Isometric Contraction

    MVIC of leg extensors at 120 degrees between thigh and leg

    Approximately 90 minutes post-ingestion of condition

  • Muscle Activation

    EMG amplitude during MVIC

    Approximately 90 minutes post ingestion

Secondary Outcomes (1)

  • Wingate Anaerobic Test

    Approximately 100 minutes post-ingestion of condition

Study Arms (2)

Supplement group

EXPERIMENTAL

Oral Alpha-GPC (900 mg)

Dietary Supplement: L-Alpha glycerylphosphorylcholine

Placebo group

PLACEBO COMPARATOR

Oral microcrystalline cellulose

Dietary Supplement: Microcrystalline Cellulose

Interventions

L-Alpha glycerylphosphorylcholineDIETARY_SUPPLEMENT

Oral, 900 mg, single dose study

Supplement group
Microcrystalline CelluloseDIETARY_SUPPLEMENT

Oral, 900 mg, single dose study

Also known as: Placebo
Placebo group

Eligibility Criteria

Age19 Years - 29 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Recreationally-trained males, college-aged

You may not qualify if:

  • If the subjects report: 1) cardiovascular disease, metabolic, renal, hepatic, or musculoskeletal disorders; 2) use of any medications; 3) use of nutritional supplements; 4) habitual use of caffeine (≥1 caffeinated beverage per day); 5) participation in another clinical trial or investigation of another nutritional product within 30 days of screening/enrollment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Northern Illinois University

DeKalb, Illinois, 60115, United States

Location

MeSH Terms

Interventions

Glycerylphosphorylcholinemicrocrystalline cellulose

Intervention Hierarchy (Ancestors)

GlycerophosphatesTriose Sugar AlcoholsSugar AlcoholsAlcoholsOrganic ChemicalsCarbohydratesGlycerophospholipidsPhosphatidic AcidsPhospholipidsMembrane LipidsLipidsLecithinsPhosphatidylcholines

Study Officials

  • Clayton Camic, PHD

    Northern Illinois University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Clayton Camic, PHD

CONTACT

13077607449ccamic1@niu.edu

Matteo de Leon, BS

CONTACT

224-864-0044claytoncamic@yahoo.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: Randomized, placebo-controlled, within-subjects, crossover design.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

February 2, 2026

First Posted

February 9, 2026

Study Start

March 16, 2026

Primary Completion

May 16, 2026

Study Completion

May 16, 2026

Last Updated

February 9, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

All raw, de-identified data will be available by the researchers upon request.

Shared Documents
STUDY PROTOCOL, SAP, ICF

Locations

US(1)